(STIM) Neuronetics - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 109m USD | Total Return: -65.3% in 12m
Avg Turnover: 3.47M
Qual. Beats: 0
Rev. Trend: 91.4%
Qual. Beats: 0
Warnings
Interest Coverage Ratio -3.5 is critical
Altman Z'' -12.57 < 1.0 - financial distress zone
Choppy Below Avwap Earnings
Tailwinds
No distinct edge detected
Neuronetics, Inc. (STIM) is a commercial-stage medical technology company focused on non-invasive treatments for neurohealth disorders. Its primary product, the NeuroStar Advanced Therapy System, utilizes transcranial magnetic stimulation (TMS) to treat adult patients diagnosed with major depressive disorder (MDD) who have failed to achieve satisfactory improvement from prior antidepressant medication.
The company operates within the Health Care Equipment sector, utilizing a direct-to-provider business model by selling systems and recurring treatment sessions to psychiatric practices. TMS technology represents a significant shift in mental health care, offering a non-systemic alternative to traditional pharmaceuticals, which often carry high systemic side-effect profiles.
Investors can evaluate detailed valuation metrics and historical performance for STIM on ValueRay. The company focuses on expanding the clinical indications for its TMS platform to increase its total addressable market within the outpatient mental health space.
- NeuroStar system utilization rates drive recurring revenue through per-treatment session fees
- Insurance reimbursement coverage expansion for TMS therapy increases patient access and volume
- Sales force productivity and psychiatrist adoption rates dictate capital equipment placement growth
- High interest rates impact customer ability to finance new system purchases
- Strategic acquisition of Greenbrook TMS consolidates market share and improves operating leverage
| Net Income: -37.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.11 > 0.02 and ΔFCF/TA 15.43 > 1.0 |
| NWC/Revenue: 12.46% < 20% (prev 40.05%; Δ -27.60% < -1%) |
| CFO/TA -0.10 > 3% & CFO -12.8m > Net Income -37.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.67 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.6m) vs 12m ago 13.22% < -2% |
| Gross Margin: 47.96% > 18% (prev 63.51%; Δ -15.55% > 0.5%) |
| Asset Turnover: 113.4% > 50% (prev 63.00%; Δ 50.41% > 0%) |
| Interest Coverage Ratio: -3.50 > 6 (EBIT TTM -29.5m / Interest Expense TTM 8.41m) |
| A: 0.15 (Total Current Assets 47.2m - Total Current Liabilities 28.3m) / Total Assets 125.4m |
| B: -3.74 (Retained Earnings -469.6m / Total Assets 125.4m) |
| C: -0.22 (EBIT TTM -29.5m / Avg Total Assets 133.7m) |
| D: 0.12 (Book Value of Equity 13.3m / Total Liabilities 108.4m) |
| Altman-Z'' = -12.57 = D |
| DSRI: 0.36 (Receivables 16.2m/26.9m, Revenue 151.6m/89.4m) |
| GMI: 1.32 (GM 63.51% / 47.96%) |
| AQI: 1.19 (AQ_t 0.41 / AQ_t-1 0.34) |
| SGI: 1.70 (Revenue 151.6m / 89.4m) |
| TATA: -0.19 (NI -37.1m - CFO -12.8m) / TA 125.4m) |
| Beneish M = -2.67 (Cap -4..+1) = A |
As of June 08, 2026, the stock is trading at USD 1.29 with a total of 2,003,229 shares traded.
Over the past week, the price has changed by -16.23%,
over one month by -29.89%,
over three months by -2.27% and
over the past year by -65.32%.
Neuronetics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy STIM.
- StrongBuy: 1
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 4.3 | 235.7% |
P/S = 0.7159
P/B = 8.7608
Revenue TTM = 151.6m USD
EBIT TTM = -29.5m USD
EBITDA TTM = -26.2m USD
Long Term Debt = 61.3m USD (from longTermDebt, last quarter)
Short Term Debt = 5.42m USD (from shortTermDebt, last quarter)
Debt = 90.8m USD (corrected: LT Debt 61.3m + ST Debt 5.42m) + Leases 24.1m
Net Debt = 77.6m USD (calculated: Debt 90.8m - CCE 13.2m)
Enterprise Value = 186.2m USD (108.6m + Debt 90.8m - CCE 13.2m)
Interest Coverage Ratio = -3.50 (Ebit TTM -29.5m / Interest Expense TTM 8.41m)
EV/FCF = -13.71x (Enterprise Value 186.2m / FCF TTM -13.6m)
FCF Yield = -7.30% (FCF TTM -13.6m / Enterprise Value 186.2m)
FCF Margin = -8.96% (FCF TTM -13.6m / Revenue TTM 151.6m)
Net Margin = -24.48% (Net Income TTM -37.1m / Revenue TTM 151.6m)
Gross Margin = 47.96% ((Revenue TTM 151.6m - Cost of Revenue TTM 78.9m) / Revenue TTM)
Gross Margin QoQ = 46.89% (prev 51.95%)
Tobins Q-Ratio = 1.48 (Enterprise Value 186.2m / Total Assets 125.4m)
Interest Expense / Debt = 9.27% (Interest Expense 8.41m / Debt 90.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -23.3m (EBIT -29.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.67 (Total Current Assets 47.2m / Total Current Liabilities 28.3m)
Debt / Equity = 6.85 (Debt 90.8m / totalStockholderEquity, last quarter 13.3m)
Debt / EBITDA = -2.96 (negative EBITDA) (Net Debt 77.6m / EBITDA -26.2m)
Debt / FCF = -5.71 (negative FCF - burning cash) (Net Debt 77.6m / FCF TTM -13.6m)
Total Stockholder Equity = 22.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.76% (Net Income -37.1m / Total Assets 125.4m)
RoE = -164.7% (Net Income TTM -37.1m / Total Stockholder Equity 22.5m)
RoCE = -35.16% (EBIT -29.5m / Capital Employed (Equity 22.5m + L.T.Debt 61.3m))
RoIC = -24.51% (negative operating profit) (NOPAT -23.3m / Invested Capital 95.0m)
WACC = 6.62% (E(108.6m)/V(199.4m) * Re(6.03%) + D(90.8m)/V(199.4m) * Rd(9.27%) * (1-Tc(0.21)))
Discount Rate = 6.03% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 47.45%
[DCF] Fair Price = unknown (Cash Flow -13.6m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.27 | # QB: 0
Revenue Correlation: 91.37 | Revenue CAGR: 37.39% | SUE: 0.14 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.12 | Chg30d=+2.68% | Revisions=+33% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.11 | Chg30d=-6.19% | Revisions=+20% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.46 | Chg30d=+2.81% | Revisions=+33% | GrowthEPS=+21.5% | GrowthRev=+8.7%
EPS next Year (2027-12-31): EPS=-0.34 | Chg30d=-5.22% | Revisions=+33% | GrowthEPS=+27.3% | GrowthRev=+11.8%
[Analyst] Revisions Ratio: +33%